Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HYPR Stock Forecast 2025-2026
$0.76
Current Price
$62.27M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to HYPR Price Targets
+96.1%
To High Target of $1.50
+30.7%
To Median Target of $1.00
-11.1%
To Low Target of $0.68
HYPR Price Momentum
+10.1%
1 Week Change
-5.0%
1 Month Change
-24.0%
1 Year Change
-13.6%
Year-to-Date Change
-59.7%
From 52W High of $1.90
+43.5%
From 52W Low of $0.53
📊 TOP ANALYST CALLS
Did HYPR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Hyperfine is one of their latest high-conviction picks.
Latest HYPR Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, HYPR has a bullish consensus with a median price target of $1.00 (ranging from $0.68 to $1.50). Currently trading at $0.76, the median forecast implies a 30.7% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 96.1% upside. Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 11.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HYPR Analyst Ratings
2
Buy
1
Hold
0
Sell
HYPR Price Target Range
Low
$0.68
Average
$1.00
High
$1.50
Current: $0.76
Latest HYPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HYPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $1.00 |
| May 14, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $0.68 |
| Mar 24, 2025 | Lake Street | Frank Takkinen | Buy | Initiates | $1.50 |
| Mar 20, 2025 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $1.20 |
| Mar 18, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $1.29 |
| Mar 22, 2024 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $1.60 |
| Nov 30, 2023 | Jefferies | Young Li | Hold | Initiates | $1.25 |
| Aug 15, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $3.50 |
| Mar 22, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $2.50 |
| Oct 4, 2022 | B. Riley Securities | Neil Chatterji | Buy | Initiates | $3.50 |
| Aug 11, 2022 | Wells Fargo | Larry Biegelsen | Equal-Weight | Downgrade | $2.40 |
| May 31, 2022 | Evercore ISI Group | Outperform | Initiates | $0.00 | |
| Apr 14, 2022 | Wells Fargo | Overweight | Initiates | $0.00 |
Hyperfine Inc. (HYPR) Competitors
The following stocks are similar to Hyperfine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hyperfine Inc. (HYPR) Financial Data
Hyperfine Inc. has a market capitalization of $62.27M with a P/E ratio of -1.4x. The company generates $11.73M in trailing twelve-month revenue with a 45.7% profit margin.
Revenue growth is -35.1% quarter-over-quarter, while maintaining an operating margin of -510.2% and return on equity of -67.9%.
Valuation Metrics
Market Cap
$62.27M
Enterprise Value
$23.20M
P/E Ratio
-1.4x
PEG Ratio
-1.5x
Price/Sales
5.3x
Growth & Margins
Revenue Growth (YoY)
-35.1%
Gross Margin
+41.3%
Operating Margin
-510.2%
Net Margin
+45.7%
EPS Growth
-35.1%
Financial Health
Cash/Price Ratio
+55.6%
Current Ratio
6.1x
Debt/Equity
0.6x
ROE
-67.9%
ROA
-39.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Hyperfine Inc. (HYPR) Business Model
About Hyperfine Inc.
What They Do
Develops portable, low-cost MRI systems.
Business Model
Hyperfine Inc. generates revenue by selling its Swoop Portable MRI systems to healthcare providers, enabling real-time imaging in various settings, such as emergency rooms and remote areas. The company focuses on making advanced medical imaging more accessible and affordable, thereby expanding its market reach and improving patient care.
Additional Information
By innovating in medical technology, Hyperfine aims to transform healthcare delivery and enhance clinical outcomes. Its products are particularly beneficial in environments with limited access to traditional MRI facilities, positioning the company as a vital player in the med-tech industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
111
CEO
Ms. Maria Sainz
Country
United States
IPO Year
2021
Website
hyperfine.ioHyperfine Inc. (HYPR) Latest News & Analysis
Latest News
Quick Summary
Hyperfine has appointed Dr. Rob Fasciano and Dr. Rafael O'Halloran to enhance and scale its AI-powered MRI technology and next-generation imaging solutions.
Why It Matters
The appointment of experienced leaders signals Hyperfine's commitment to innovation in AI-driven MRI technology, potentially enhancing market position and attracting investment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
HYPR has received FDA clearance for its Swoop system, enhancing bedside MRI technology and aiming to improve accessibility in neuroimaging.
Why It Matters
FDA clearance for HYPR's Swoop system boosts its market potential in neuroimaging, likely increasing revenue prospects and attracting investor interest in innovative medical technology.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The FDA has approved the next-gen Swoop® MRI system featuring Optive AI™ software, enhancing image quality, usability, and comfort.
Why It Matters
The FDA clearance of the Swoop® MRI system with advanced AI boosts the company's market position, potentially increasing sales and attracting investor interest in innovative healthcare technologies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Hyperfine, Inc. (Nasdaq: HYPR) received FDA clearance for its next-gen Optive AI™ software, improving image quality for its portable MRI system, the Swoop®, enhancing ultra-low-field MR imaging.
Why It Matters
Hyperfine's FDA clearance for its advanced imaging software boosts product quality, potentially increasing demand and revenue, which could positively impact its stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Hyperfine, Inc. (Nasdaq: HYPR) will present at the Jefferies Global Healthcare Conference on June 5 at 4:20 PM ET and host in-person meetings on June 4.
Why It Matters
Hyperfine's presentation at a major healthcare conference highlights its innovative product and potential for growth, signaling opportunities for investors in the health tech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Hyperfine, Inc. (NASDAQ:HYPR) will hold its Q1 2025 earnings conference call on May 13, 2025, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters
Hyperfine's upcoming earnings call on May 13, 2025, will provide insights into its financial performance and strategic direction, influencing stock price and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About HYPR Stock
What is Hyperfine Inc.'s (HYPR) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Hyperfine Inc. (HYPR) has a median price target of $1.00. The highest price target is $1.50 and the lowest is $0.68.
Is HYPR stock a good investment in 2026?
According to current analyst ratings, HYPR has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HYPR stock?
Wall Street analysts predict HYPR stock could reach $1.00 in the next 12 months. This represents a 30.7% increase from the current price of $0.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Hyperfine Inc.'s business model?
Hyperfine Inc. generates revenue by selling its Swoop Portable MRI systems to healthcare providers, enabling real-time imaging in various settings, such as emergency rooms and remote areas. The company focuses on making advanced medical imaging more accessible and affordable, thereby expanding its market reach and improving patient care.
What is the highest forecasted price for HYPR Hyperfine Inc.?
The highest price target for HYPR is $1.50 from Frank Takkinen at Lake Street, which represents a 96.1% increase from the current price of $0.76.
What is the lowest forecasted price for HYPR Hyperfine Inc.?
The lowest price target for HYPR is $0.68 from Larry Biegelsen at Wells Fargo, which represents a -11.1% decrease from the current price of $0.76.
What is the overall HYPR consensus from analysts for Hyperfine Inc.?
The overall analyst consensus for HYPR is bullish. Out of 6 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are HYPR stock price projections?
Stock price projections, including those for Hyperfine Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 3:14 AM UTC